Price movement over the last 24 hours
Agilent Technologies Inc vs Colgate-Palmolive Company — how do they compare? Agilent Technologies Inc trades at $128.78 (market cap $37.04B), while Colgate-Palmolive Company trades at $93.3 (market cap $76.04B). The key difference: Colgate-Palmolive Company is far larger — about 2.1× Agilent Technologies Inc's market cap, and Colgate-Palmolive Company pays the higher dividend (2.23%). Which is the better fit depends on your goals.
| A | CL | |
|---|---|---|
Market Cap | $37.04B | $76.04B |
Sector | Health | Consumer Staples |
52-Week High | $157.20 | $99.14 |
52-Week Low | $110.24 | $74.98 |
Enterprise Value | $38.59B | $82.68B |
Dividend Yield | 0.78% | 2.23% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Colgate-Palmolive (CL) trades at $95.03, down 0.11% on the day, with a bullish technical outlook supported by moving averages and recent earnings beats. The company maintains strong profitability with a 60.06% gross margin and 10.04% net margin, though its P/E of 36.2 and P/B of 515.38 reflect premium valuation. Positive sentiment is driven by dividend consistency and strategic growth initiatives, while cash flow trends show stable operational performance.
Outlook remains cautiously optimistic with analyst consensus at Buy 42%, Hold 53%, and a $95.50 price target. Key opportunities include international growth and pricing power, but risks involve North American softness and high valuation multiples. The stock's 17% YTD gain underscores resilience, though inflation and competitive pressures warrant monitoring for sustained outperformance.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →